8月14日，再鼎医药盘中下跌5.29%，报19.51港元，成交额4631.99万港元。公司自8月6日公布Q2业绩以来股价累计涨幅超三成，短期获利回吐压力显现。
板块层面，生物科技行业今日整体承压，康方生物跌2.99%、百济神州跌1.91%、三生制药跌1.29%。基本面上，虽RTW基金近日连续斥资约3.68亿美元大幅增持彰显信心，但有机构指出则乐面临竞品集采压力、艾加莫德价格承压，并下调盈利预测，短期估值快速修复后市场对中期盈利能力分歧加大。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.